Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Cardiovascular Associates Research LLC

Neither a doctor nor a teaching hospital

Research payments

$351,610

567 payments

Through program year 2025, Cardiovascular Associates Research LLC is reported as receiving $351,610 in research payments, across 567 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $52,819 1
2024 Research $7,443 6
2023 Research $7,313 7
2022 Research $16,793 9
2021 Research $73,042 157
2020 Research $106,476 327
2019 Research $87,723 60

Breakdown

Who paid Research payments · program years 2019–2025
  1. Kowa Research Institute, Inc. $104,175 37 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $83,986 48 payments
  3. Biotronik Inc. $68,736 468 payments
  4. Amgen Inc. $52,819 1 payment
  5. Sanofi US Services Inc. $31,940 12 payments
  6. Lexicon Pharmaceuticals, Inc. $9,954 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. K-877-302 $71,377 22 payments
  2. BIO-Precision $62,543 433 payments
  3. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity $52,819 1 payment
  4. K-877-302 $32,798 15 payments
  5. BAY94-8862 LCM HFmr/pEF (EF 40%) $24,106 16 payments
  6. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes POST Worsening Heart Failure $23,840 7 payments
  7. BAY59-7939 2.5mg reduction atherothrombotic events vs. ASA $18,221 10 payments
  8. A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) $17,400 7 payments
  9. Multicenter randomized placebo controlled double-blind parallel group dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infarction $16,816 9 payments
  10. Efc15156 $9,954 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record